Conclusions
Investigators concluded that these ADHD medications may improve subjective executive function, but ultimately not cognition, by modulating catecholaminergic pathways that are often disrupted during the menopause transition. Additionally, cross-sectional evidence suggests that baseline ADHD symptom severity is associated with greater perimenopausal symptom burden.
“For most women, brain fog at menopause is a temporary condition that does not lead to permanent cognitive changes or dementia. However, it can last long enough to disrupt work and daily routines and cause significant stress and anxiety. That is why studies like this are important in helping to identify additional options for symptoms,” says Stephanie Faubion, MD, medical director for The Menopause Society.
These findings could lead to a nonhormone therapeutic option for addressing perimenopausal executive dysfunction. However, larger studies must first confirm whether these medications are safe and effective for this use before they can be recommended as a treatment option.
Unmet Need
Approximately 44% to 60% of perimenopausal women report cognitive changes like forgetfulness and trouble concentrating, or brain fog. During the menopause transition, there is a significant decline and fluctuation in estrogen which mediates catecholaminergic signaling within the prefrontal cortex. This neurobiological shift results in brain fog, involving quantifiable deficits in working memory, attentional control, and processing speed that mirror the core symptom domains of ADHD.
Despite this, there are currently no FDA-approved pharmacological interventions for brain fog.
Next Steps
Details of the study will be discussed as part of the presentation, “Brain Fog or ADHD? Executive Dysfunction in Perimenopause: A Scoping Review of the Role of ADHD Medications,” at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.
References
1.